Company / SG&A Expense
Biohaven Ltd. SG&A Expense History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$89.2M
FY2024
5-year range
$16.0M / $130.9M
FY2020-FY2024
Trend
+42.2%
vs FY2023
Sector context
#121 of 213
Health Care
What the data says
At $89M, Biohaven Ltd.'s sg&a expense ranks #93 of 213 in the Health Care sector. Improved from $131M to $89M over the past 2 years.
Based on SEC 10-K filings.
$89M in FY2024 with a 3-year CAGR of +33.6%.
Improved from $131M to $89M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +33.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#93 of 213 in Health CareTop 43% of 213This company $89.2M Sector average $722.3M
▼
-87.6% below sector average
Key checks
Key Insights
- 3-year CAGR of +33.6%, indicating consistent growth.
- In FY2024, sg&a expense increased 42.2% year-over-year.
- Ranks #121 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $89.2M | +42.2% |
| FY2023 | $62.8M | -52.0% |
| FY2022 | $130.9M | +249.8% |
| FY2021 | $37.4M | +133.2% |
| FY2020 | $16.0M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026